MSN sells US copies of 1 of the blockbuster drugs on this tracker, is approved for 6 more, and has 3 filed or in development. Those brands earned $41.0B in 2025. Of the 70 makers we follow, 6 are lined up to copy more of these drugs.
| Drug | MSN's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| EntrestoGeneric · Novartis · US LOE 2025 | FDA-approved 16 Jul 2025; launched Jul 2025; first filer; FDA has not decided whether it keeps 180-day shared exclusivity. Sells through Novadoz; first US generic | 1 on sale · 14 approvedof 15 other makers listed | $7.7B |
| Drug | MSN's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| XareltoGeneric · Bayer / Johnson & Johnson · US LOE 2025 | FDA-approved 24 Oct 2025 | 1 on sale · 17 approvedof 19 other makers listed | ≈$5.3B |
| FarxigaGeneric · AstraZeneca · US LOE 2026 | FDA-approved 6 Apr 2026 | 2 on sale · 12 approvedof 14 other makers listed | $8.4B |
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 2 Sep 2026 | 4 on sale · 5 approvedof 10 other makers listed | $2.7B |
| OpsumitGeneric · Johnson & Johnson · US LOE 2026 | FDA-approved 20 Aug 2025 | 2 on sale · 9 approvedof 11 other makers listed | $2.3B |
| OtezlaGeneric · Amgen · US LOE 2028 | FDA-approved 16 Dec 2024 | 0 on sale · 4 approvedof 8 other makers listed | $2.3B |
| CabometyxGeneric · Exelixis · US LOE 2031 | FDA-approved 14 Aug 2026; barred by court until 15 Jan 2030 | 0 on sale · 2 approvedof 5 other makers listed | $2.1B |
| Drug | MSN's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| JakafiGeneric · Incyte · US LOE 2028 | Filed with the FDA; in litigation | 0 on sale · 0 approvedof 9 other makers listed | $3.1B |
| CalquenceGeneric · AstraZeneca · US LOE 2032 | Filed with the FDA; settled Dec 2025, terms confidential | 0 on sale · 0 approvedof 1 other maker listed | $3.5B |
| ErleadaGeneric · Johnson & Johnson · US LOE 2033 | Filed with the FDA; in litigation, sued Jun 2026 | 0 on sale · 1 approvedof 3 other makers listed | $3.6B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not MSN's own sales. See the launch tracker →
Each row is a copy MSN sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not MSN's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not MSN's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: ZaubaCorp company record.